BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients ...

Please provide your email address to receive an email when new articles are posted on . Researchers have proposed a machine-learning algorithm for personalized treatment selection in patients with ...

Researchers have developed a new AI-powered algorithm to help understand how different cells organize themselves into particular tissues and communicate with one another. Researchers from Children's ...

Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...